Sign in
Not yet taking people in CzechiaPhase 2

Tests a stool bacteria transfer for autism symptoms in children

Tests whether transplanted gut bacteria from stool change core autism symptoms in children.

Key facts

Who runs it
Masarykova Univerzita
Where
Brno, CzechiaSee the site
Registry title
Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinical trial (FMT-PAS)
Status
Not yet recruiting
Phase
Phase 2
People taking part
20 people, planned
Started
1 Sept 2026
Expected to end
31 Dec 2029
Type of study
Interventional
Record updated
17 March 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for children aged 3 to 12 years with autism spectrum disorder confirmed by a specialist, who speak only a few words.

Age
3 to 12 years
Sex
All sexes
Disease stage
Autism spectrum disorder confirmed by a clinical psychologist or psychiatrist, with an earlier ADOS-2 result in the ASD range and only minimum verbal ability (ADOS-2 Module 1).
Earlier treatment
No new or recently changed behavioural, cognitive or cognitive-behavioural therapy or medicine in the last 30 days. No immunosuppressants, antiplatelet drugs, anticoagulants, antibiotics, probiotics, prebiotics or postbiotics now or in the last 3 months.

Main reasons for not taking part

  • Birth defect or primary disease of the digestive tract, including coeliac disease
  • Early reaction to food in the medical history
  • Cannot take the bowel preparation, for example cannot use liquid medicine
  • Cannot have sedation, or had serious problems with sedation before
  • Weak immune system, or severe other conditions such as psychosis, epilepsy not controlled by medicine, or severe vision or hearing loss

The registry criteria, word for word

Show all 15 criteriaShow less

Who can take part

  • Age 3–12 years
  • Diagnosis of ASD confirmed by a clinical psychologist or psychiatrist
  • Previous ADOS-2 examination result in the ASD range
  • Only minimum verbal ability (i.e. corresponding to ADOS-2, Module 1)
  • Informed consent of the parent (legal representative) and willingness to follow all planned study visits and instructions, especially for bowel preparation

Who cannot take part

  • Newly initiated or recently changed formal behavioural, cognitive or cognitive-behavioural therapy (less than 30 days before enrolment)
  • Expected inability to undergo bowel preparation (e.g. child’s inability to use liquid medication declared by parent)
  • Contraindication for common sedative medication, or serious complications of sedation in the patient’s medical history
  • Use of antiplatelet drugs, anticoagulants, or systemic antibiotics at present or in the last 3 months
  • Newly initiated or recently changed pharmacotherapy (less than 30 days before enrolment)
  • Congenital GIT defect or primary GIT disease, incl. medically confirmed coeliac disease (gluten enteropathy)
  • Severe co-morbid conditions (e.g. psychosis, epilepsy uncontrolled by medication, presence of severe visual or hearing impairment) that may interact with study procedures (at discretion of the investigator)
  • Early reaction to food in the patient’s medical history
  • Use of systemic immunosuppressants at present or in the last 3 months, or present medically confirmed immunocompromised status
  • Use of probiotics, prebiotics, or postbiotics at present or in the last 3 months

Where in Czechia

  • Fakultni nemocnice BrnoBrno, CzechiaNot yet recruiting

About the trial

What the trial wants to find out

The primary objective of the trial is to describe the effect of faecal microbiota transplant (FMT) on autism spectrum disorder core symptoms.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
Official title
Effect of faecal microbiota transplant on the expression of autism spectrum disorder core symptoms in children – open-label phase II clinical trial (FMT-PAS)
Plain-language title
Tests a stool bacteria transfer for autism symptoms in childrenGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
17 March 2026